FDA cites Pfizer on Lipitor web page; FDA warns on allergic reactions to Merck antipsychotic;

@FiercePharma: Tarceva's new European OK points up Roche's targeted goals. Item | Follow @FiercePharma

> The FDA has scolded Pfizer ($PFE) for links off its Lipitor website leading to product info on the cardiovascular drugs Norvasc and Caduet and the stop-smoking treatment Chantix. Report

> Merck's ($MRK) antipsychotic drug Saphris can trigger serious allergic reactions, the FDA warned; the drug's label has been changed accordingly. Article

> Lupin has struck a deal to market and distribute Sanofi's ($SNY) antipsychotic Solian and insomnia remedy Stilnox in the Philippines through its domestic unit Multicare Pharmaceuticals. Story

> Merck KGaA's cancer treatment Erbitux and Novartis' ($NVS) multiple sclerosis drug Gilenya won spots on Australia's formulary of subsidized medicines. Piece

> South Africa's Aspen Pharmacare, 19%-owned by GlaxoSmithKline ($GSK), expects to beat analyst estimates with a 22% profit rise for its full fiscal year. Report

> Pfizer ($PFE) extended its Icagen offer by another 18 hours as it looks to eke out a tender-offer victory; only 39,799 more shares to go. News

> Merck ($MRK) wrapped up an addition and expansion at its animal vaccine facility in Elkhorn, NE. Item

Biotech News

@FierceBiotech: Synageva inks orphan drug R&D deal with Mitsubishi Tanabe Pharma, grabs $3M upfront. News | Follow @FierceBiotech

@JohnCFierce: Oxigene says it still can't raise cash, has to lay off more people. Going, going.... Report | Follow @JohnCFierce

@RyanMFierce: Would the extra 60-day filing period for FDA reviews of new drugs actually bring the treatments to market sooner? | Follow @RyanMFierce

> Merck Serono opens doors at R&D shop in Beijing. Details

> Genzyme gives back drug rights to PTC Therapeutics. News

> FDA, industry seek extended reviews for new drugs. Article

> Mitsubishi Tanabe Pharma taps Synageva for orphan disease R&D. Report

> September is Fierce. Mark your calendars now. Piece

And Finally... Prescribing rates for children's antibiotics are dropping, but not quickly enough for the CDC. Report

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.